再結合因子VIIaがヒトにおける組織因子の阻害中にトロンビンを生成する能力
P W Friederich1, M Levi, K A Bauer
1Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Netherlands.
Circulation
|May 31, 2001
まとめ
再結合因子VIIa (rVIIa) は,組織因子阻害剤であるネモトード抗凝固タンパク質c2の抗凝固効果を逆転させることができる. この発見は,rVIIaが組織因子経路阻害剤に関連した出血合併症の効果的な解毒剤として機能することを示唆しています.
科学分野:
- ヘモスタシスとトランボシス
- 薬理学 薬理学とは
- バイオケミストリー バイオケミストリー
背景:
- 組織因子-因子VIIa経路は,血液凝固の開始に不可欠です.
- この経路を標的とする新型抗凝固剤は,出血イベントの有効な逆転戦略を必要とします.
- 再結合性ネマトード抗凝固タンパク質c2 (rNAPc2) は,組織因子-因子VIIa複合体の特定の阻害剤である.
研究 の 目的:
- 再結合因子VIIa (rVIIa) がトロンビン生成を誘発するインビヴォの可能性を調査する.
- 健康な被験者におけるrNAPc2の抗凝固効果を逆転させるためのrVIIaの有効性を評価する.
主な方法:
- ダブルブラインドランダム化クロスオーバー研究設計.
- 健康なボランティアにrNAPc2を投与し,その後はrVIIaを投与した.
- プロトロンビン時間,プロトロンビン活性化断片F1+2,およびトロンビン-反トロンビン複合体のモニタリング.
主要な成果:
- rNAPc2投与はプロトロンビン時間を延長しました.
- その後のrVIIa注射は,プロトロンビン時間を急速に修正し,有意なトロンビン生成を誘導しました.
- rVIIa投与後,F1+2およびトロンビン-アンチトロンビン複合体の濃度の上昇が観察されました.
- X因子とIX活性化ペプチドは大幅な増加を示した.
結論:
- 再結合因子VIIaは,組織因子-因子VIIa複合体阻害剤の治療中にさえも,効果的にトロンビン生成を誘導する.
- rVIIaは,組織因子経路阻害剤の効果を逆転させるための有効な解毒剤としての可能性を実証しています.
- この研究は,新しい抗凝固剤療法に関連する出血合併症を管理するための有望な治療戦略を強調しています.
関連する概念動画
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.